Karyopharm Therapeutics Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Karyopharm Therapeutics stock has a consensus rating of "Buy" and an average price target of $13.5. The average 1-year stock price forecast is 55.35% higher than the current stock price, while the lowest is $7.00 (-19.45%) and the highest is $16 (+84.12%).

Price Target: $13.5 (+55.35%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$7.00	$13.5	$14.5	$16
Change	-19.45%	+55.35%	+66.86%	+84.12%

Analyst Ratings

The average analyst rating for Karyopharm Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	4	4	4	4	4
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	7	7	7	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Leerink Partners No rating	Leerink Partners	Hold Reiterates $5 → $7	Hold	Reiterates	$5 → $7	-19.45%	May 15, 2026
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $16	Buy	Maintains	$16	+84.12%	May 15, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $8 → $13	Buy	Reiterates	$8 → $13	+49.60%	May 7, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $8 → $16	Buy	Reiterates	$8 → $16	+84.12%	Apr 27, 2026
Colleen M. Kusy Robert W. Baird	Robert W. Baird	Buy Maintains $21 → $15	Buy	Maintains	$21 → $15	+72.61%	Mar 25, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

137.21M

from 146.07M

-6.06%

from 146.07M

Revenue Next Year

155.30M

from 137.21M

13.18%

from 137.21M

EPS This Year

-4.95

from -12.22

EPS Next Year

-4.89

from -4.95

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	209.82M	157.07M	146.03M	145.24M	146.07M	137.21M
Revenue Growth	94.12%	-25.14%	-7.03%	-0.55%	0.57%	-6.06%
Gross Profit	206.42M	3.20M	2.34M	-4.00M	14.50M	131.17M
Gross Margin	98.38%	2.04%	1.60%	-2.76%	9.93%	95.60%
Operating Income	-98.27M	-142.20M	-129.54M	-119.44M	-90.71M	-110.64M
Net Income	-124.09M	-165.29M	-143.10M	-76.42M	-196.04M	-127.84M
EPS	-	-	-	-	-12.22	-4.95
Free Cash Flow	-58.64M	-101.35M	-39.95M	-77.09M	-49.43M	143.10M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	157.8M
Avg	137.2M
Low	123.8M

Revenue Growth

Revenue Growth	2026	2027	2028
High	8.0%
Avg	-6.1%
Low	-15.2%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-4.95
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-